- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04202835
ATG Plus PTCy vs ATG for CGVHD Prophylaxis
March 14, 2023 updated by: McMaster University
A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD)
A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Patients with acute leukemia or myelodysplastic syndrome will be randomized to receive, or not receive, post transplant cyclophosphamide in addition to anti-thymocyte globulin.
Study Type
Interventional
Enrollment (Anticipated)
80
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sarah Garisto, BSc
- Phone Number: 1 416 634 8300
- Email: sarah.garisto@ozmosisresearch.ca
Study Locations
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
- Recruiting
- Kinghorn Cancer Centre, St Vincent's Health Network
-
Contact:
- Louise Christophersen
-
St. Leonards, New South Wales, Australia, 2065
- Recruiting
- Royal North Shore Hospital
-
Contact:
- Molly Forbes
-
-
Victoria
-
Melbourne, Victoria, Australia, 3121
- Recruiting
- Australasian Leukaemia and Lymphoma Group
-
Contact:
- Nada Hamad, MBBS MSc
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- Recruiting
- CancerCare Manitoba
-
Contact:
- Kristjan Paulson, MD
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Recruiting
- Queen Elizabeth II Health Sciences Centre
-
Contact:
- Mahmoud Elsawy, MD
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 1C3
- Recruiting
- Juravinski Hospital and Cancer Centre
-
Contact:
- Irwin Walker, MBBS
- Phone Number: 76384 905 521 2100
- Email: walkeri@mcmaster.ca
-
London, Ontario, Canada, N6A 5W9
- Recruiting
- London Health Sciences Centre
-
Contact:
- Uday Deotare, MD
-
-
Quebec
-
Québec City, Quebec, Canada, G1R 2J6
- Recruiting
- Hôpital de L'Enfant-Jésus
-
Contact:
- Geneviève Gallagher, MD
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Recruiting
- Saskatchewan Cancer Agency
-
Contact:
- Mohamed Elemary, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 70 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The participant is aged ≥ 16 and deemed medically fit per investigator for protocol
- The participant has either acute myeloid leukemia in 1st or 2nd complete remission (CR), or has myelodysplastic syndrome
- The participant will receive a blood progenitor cell graft ("HPC, Apheresis")
- The participant has a related or unrelated donor, who is fully MHC matched with the recipient at HLA-A, B, C and DRB1.
- The participant meets the transplant centre's criteria for transplantation, using either myeloablative or reduced intensity conditioning.
- The participant has good performance status (Karnofsky ≥60%)
- The participant is able to understand and sign the informed consent form
- Ability and willingness to comply with study procedures and schedule, in the Investigator's opinion.
- The participant is receiving their first transplant
Exclusion Criteria:
- The participant is HIV antibody positive
- The participant has a hypersensitivity to rabbit proteins or Thymoglobulin® pharmaceutical excipients, glycine or mannitol.
- The participant has active or chronic infection (i.e. infection requiring oral or IV therapy)
- The participant (if female and of childbearing potential) is pregnant or breast-feeding at the time of enrollment
- The participant (if female and of childbearing potential) does not agree to use an adequate contraceptive method from the time of enrollment until a minimum of one year following transplant3
- The participant (if male and fertile) does not agree to use an adequate contraceptive method from the time of enrollment until a minimum of one year following transplant3
- The participant has urinary outflow obstruction
- The participant is in poor condition (determined per institutional guidelines)
- The participant has acute leukemia in relapse
- The participant has myelodysplastic syndrome with > 10% marrow blasts
- The participant is having their second transplant
- The participant is taking T-cell antibody prophylaxis (anti-CD52)
- The participant is receiving a cord blood graft or T-cell depleted grafts
- The participant has mixed phenotype acute leukemia
- The participant has prior malignancies, except resected nonmelanoma or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously must be reviewed and approved by the sponsors.
- The participant is in complete remission with incomplete recovery (CRi)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ATG/PTCy
Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1); cyclophosphamide (Post Transplant Cyclophosphamide, PTCy) 50 mg/kg IV daily on days +3 and +4.
|
Post Transplant Cyclophosphamide
Anti-Thymocyte Globulin (rabbit, Thymoglobulin)
Other Names:
|
Active Comparator: ATG
Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1).
|
Anti-Thymocyte Globulin (rabbit, Thymoglobulin)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Registration of 80 patients within twenty four months
Time Frame: 24 months
|
Registration will be documented by the Clinical Research Organization (Ozmosis Research Inc.)
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CRFS
Time Frame: 27 months
|
Chronic graft versus host disease free- and relapse-free survival (CRFS)
|
27 months
|
GRFS
Time Frame: 27 months
|
Graft versus host disease-, and relapse-, free survival (GRFS)
|
27 months
|
Survival
Time Frame: 27 months
|
Survival (dead/alive) at 100 days for each patient
|
27 months
|
Complete data collection
Time Frame: 27 months
|
The Clinical Research Organization (Ozmosis Research Inc.) will document completeness of data collection
|
27 months
|
Cost of study
Time Frame: 27 months
|
The sponsor (McMaster University) and the Clinical Research Organization (Ozmosis Research Inc.) will compare actual total trial costs in Canadian dollars at trial completion (at completion of outcomes analysis and report) with expected costs as determined for the trial budget.
|
27 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Irwin R Walker, MBBS, McMaster University
- Principal Investigator: Kristjan Paulson, MD, CancerCare Manitoba
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 13, 2020
Primary Completion (Anticipated)
October 13, 2024
Study Completion (Anticipated)
December 31, 2024
Study Registration Dates
First Submitted
November 29, 2019
First Submitted That Met QC Criteria
December 17, 2019
First Posted (Actual)
December 18, 2019
Study Record Updates
Last Update Posted (Actual)
March 15, 2023
Last Update Submitted That Met QC Criteria
March 14, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms
- Bone Marrow Diseases
- Hematologic Diseases
- Precancerous Conditions
- Myelodysplastic Syndromes
- Preleukemia
- Graft vs Host Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Thymoglobulin
- Antilymphocyte Serum
Other Study ID Numbers
- CTTC1901
- OZM-099 (Other Identifier: Ozmosis Research Inc)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Leukemia
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia With Maturation | Adult Acute Myeloid Leukemia Without Maturation | Adult Acute Myelomonocytic Leukemia | Alkylating Agent-Related Acute Myeloid... and other conditionsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
National Cancer Institute (NCI)TerminatedAdult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Erythroleukemia (M6) | Childhood Acute Megakaryocytic Leukemia (M7) | Childhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia With Maturation (M2) | Childhood Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States
-
Roswell Park Cancer InstituteGlaxoSmithKlineTerminatedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedAdult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia and other conditionsCanada
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedAdult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic... and other conditionsUnited States
Clinical Trials on Cyclophosphamide
-
Children's Hospital Los AngelesLucile Packard Children's HospitalTerminatedMetabolic Diseases | Stem Cell Transplantation | Chronic Granulomatous Disease | Bone Marrow Transplantation | Thalassemia | Wiskott-Aldrich Syndrome | Genetic Diseases | Peripheral Blood Stem Cell Transplantation | Pediatrics | Diamond-Blackfan Anemia | Allogeneic Transplantation | Combined Immune Deficiency | X-linked Lymphoproliferative Disease
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedAnemia, AplasticUnited States
-
Columbia UniversityUnknownSevere Combined Immunodeficiency | Fanconi Anemia | Bone Marrow Failure | OsteopetrosisUnited States
-
National Cancer Institute, NaplesImmatics Biotechnologies GmbH; CureVac; European Commission -FP7-Health-2013-Innovation-1CompletedHepatocellular CarcinomaBelgium, Germany, Italy, Spain, United Kingdom
-
Mahidol UniversityTerminatedRenal Insufficiency | InfectionThailand
-
Eisai Inc.CompletedBreast Cancer | Ovarian Cancer | Prostate Cancer | Colon Cancer | Renal CancerUnited States
-
Centre Oscar LambretCompleted
-
Baylor Research InstituteCompletedMalignant Melanoma Stage IVUnited States
-
University of Turin, ItalyUnknown
-
Merck KGaA, Darmstadt, GermanyCompleted